The business model of Vericel Corp revolves around the development and commercialization of innovative cell therapy products. Vericel focuses on using advanced cellular and regenerative medicine technologies to provide treatments for patients with severe diseases and conditions. The company's portfolio includes products such as MACI, an autologous cellularized scaffold for the repair of symptomatic, full-thickness cartilage defects of the knee, and Epicel, a permanent skin replacement for patients with deep dermal or full-thickness burns. Vericel Corp aims to address unmet medical needs and improve the lives of patients through its cutting-edge cell therapy solutions.

Vericel Corp is primarily active in the biotechnology industry.

Vericel Corp, established in 1989, is a leading biopharmaceutical company specializing in the development and commercialization of innovative cell therapies. With headquarters in Cambridge, Massachusetts, Vericel focuses on delivering transformative therapies to patients with serious medical conditions. The company initially operated under the name Aastrom Biosciences and rebranded as Vericel in 2014. Over the years, Vericel Corp has made significant advancements in the field of regenerative medicine, particularly in utilizing a patient's own cells to create personalized therapies. With a strong commitment to research, development, and clinical trials, Vericel continues to make strides in providing groundbreaking treatments to improve patients' lives.

Vericel Corp has achieved several significant milestones since its inception. The company has successfully developed and gained FDA approval for two pioneering treatments, MACI and Epicel. MACI is a breakthrough therapy for the repair of adult knee cartilage defects, offering long-lasting pain relief and improved function for patients. On the other hand, Epicel is an advanced treatment for severe burns, providing a permanent solution for covering large burn areas. Vericel Corp has also expanded its presence in the market through strategic collaborations and partnerships, strengthening its position as a leading innovator in the regenerative medicine field.

Vericel Corp is primarily present in the United States.

Vericel Corp represents a commitment to improving patients' lives through innovative cell therapy solutions. The company seeks to develop and commercialize therapies that restore or regenerate damaged tissues. Vericel Corp espouses integrity, excellence, and patient focus as its core values. With a passion for scientific advancement and dedication to delivering transformative treatments, Vericel Corp strives to positively impact the lives of patients and healthcare providers. By leveraging cutting-edge research and technology, the company aims to address significant unmet medical needs and improve outcomes in areas such as orthopedic and cardiac care.

Analysts currently set an average price target of 56,10 USD for the Vericel stock (median: 57,63 USD), implying +26,9 % versus the latest price. The consensus is based on 13 analyst ratings.

Vericel Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Vericel stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Vericel to generate revenue of 336,22 M USD and earnings per share of 0,50 USD.

Vericel Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Vericel share trades at 38,15 EUR (44,20 USD).

The Vericel share (VCEL) is listed on 4 stock exchanges, including: NASDAQ (VCEL), Frankfurt (ATQP.F), München (ATQP.MU), Düsseldorf (ATQP.DU).

Vericel Corp is a leading biopharmaceutical company specializing in the development, manufacturing, and marketing of products for the regeneration of human tissue. The company focuses on researching and developing top-tier therapeutic options for critical medical needs that have previously been unmet. One important area of the company is the extraction, cultivation, and processing of autologous cells and tissues. Vericel's products are derived from the patient's own tissue, making them particularly safe and suitable for use. The company offers innovative treatment options based on the use of autologous cells and tissues obtained from the skin, bone marrow, adipose tissue, and other tissues. The flagship product, MACI, is a cell transplantation product used to treat knee cartilage damage in adult patients. MACI is unique in that the process of autologous tissue engineering is employed in its production, facilitating the regeneration of the patient's cartilage. Vericel's second area of focus is the treatment of patients with severe burns. This area includes the use of the product Epicel, which is used to treat large burn wounds. Epicel is created by applying an autologous keratinocyte cell suspension film to the wound, resulting in rapid and effective wound healing. Vericel also has an extensive clinical pipeline focused on tissue regeneration and the treatment of degenerative diseases. The company is working on developing autologous cell therapies to improve outcomes for patients with myocardial infarction and various neurological conditions such as ALS, Huntington's disease, and Parkinson's disease. To sustain and expand its business, Vericel collaborates with a variety of partners including hospitals, clinics, and practices. The company also has a strong marketing initiative to raise awareness of its innovative products and their medical benefits. In conclusion, Vericel Corp's business model is based on the development of novel and innovative therapeutic options using autologous cells and tissues. These therapies have great potential to aid patients with previously unmet medical needs. Through a strong marketing initiative, partnerships, and an extensive clinical pipeline, the company strives for steady growth and success.

odotettu liikevaihto Vericel on 336,22 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Vericel on 26,09 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Vericel:n hinta-voitto-suhde (P/E) on tällä hetkellä 88,20. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Vericel-osakkeen arvostusta.

Vericel:n hinta-myynti-suhde (P/S) on tällä hetkellä 6,85. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Vericel-osakkeen arvostuskennuslukuna.

Vericel:n Eulpool-laatuscore on 6/10.

Vericel:n ISIN on US92346J1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Vericel:n WKN on A12FU4. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Vericel:n ticker on VCEL. Tämä pörssinoteeraus käytetään Vericel-osakkeiden kauppaan pörssissä.

Vericel maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Vericel kuuluu sektoriin 'Terveydenhuolto'.

Vericel:n osingot jaetaan valuutassa USD.